Pfizer Inc. (NYSE:PFE) Position Increased by Simmons Bank

Simmons Bank lifted its position in Pfizer Inc. (NYSE:PFE) by 1.9% in the 4th quarter, Holdings Channel reports. The fund owned 277,480 shares of the biopharmaceutical company’s stock after buying an additional 5,070 shares during the period. Simmons Bank’s holdings in Pfizer were worth $7,989,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in PFE. Beacon Financial Advisory LLC grew its position in Pfizer by 3.4% in the 3rd quarter. Beacon Financial Advisory LLC now owns 29,245 shares of the biopharmaceutical company’s stock worth $970,000 after purchasing an additional 956 shares during the last quarter. Canal Capital Management LLC raised its stake in shares of Pfizer by 2.4% in the third quarter. Canal Capital Management LLC now owns 21,326 shares of the biopharmaceutical company’s stock worth $707,000 after acquiring an additional 506 shares during the last quarter. Concord Wealth Partners grew its holdings in Pfizer by 51.9% during the 3rd quarter. Concord Wealth Partners now owns 15,843 shares of the biopharmaceutical company’s stock worth $526,000 after acquiring an additional 5,412 shares during the period. JB Capital LLC lifted its stake in Pfizer by 22.0% in the third quarter. JB Capital LLC now owns 154,540 shares of the biopharmaceutical company’s stock valued at $5,126,000 after buying an additional 27,868 shares during the period. Finally, ETF Store Inc. boosted its stake in Pfizer by 12.0% during the 3rd quarter. ETF Store Inc. now owns 6,803 shares of the biopharmaceutical company’s stock worth $214,000 after acquiring an additional 727 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on PFE shares. Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a research report on Monday, April 15th. Argus downgraded Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Guggenheim assumed coverage on Pfizer in a report on Friday, February 23rd. They set a “buy” rating and a $36.00 price target for the company. BMO Capital Markets restated an “outperform” rating and set a $36.00 price objective (up previously from $33.00) on shares of Pfizer in a report on Thursday, May 2nd. Finally, Morgan Stanley boosted their price objective on Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a report on Thursday, May 2nd. Eleven research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $36.00.

Pfizer Stock Performance

PFE traded up $0.47 during midday trading on Wednesday, reaching $28.24. The company had a trading volume of 25,859,062 shares, compared to its average volume of 43,375,301. The business has a 50-day moving average price of $26.92 and a two-hundred day moving average price of $28.12. Pfizer Inc. has a 12-month low of $25.20 and a 12-month high of $40.37. The stock has a market cap of $159.91 billion, a PE ratio of -466.42, a P/E/G ratio of 1.17 and a beta of 0.63. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.91.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 EPS for the quarter, beating analysts’ consensus estimates of $0.56 by $0.26. Pfizer had a positive return on equity of 8.58% and a negative net margin of 0.56%. The firm had revenue of $14.88 billion for the quarter, compared to analysts’ expectations of $13.87 billion. During the same quarter in the prior year, the firm earned $1.23 EPS. The business’s revenue for the quarter was down 19.5% compared to the same quarter last year. On average, sell-side analysts expect that Pfizer Inc. will post 2.39 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 14th. Stockholders of record on Friday, May 10th will be given a $0.42 dividend. This represents a $1.68 annualized dividend and a dividend yield of 5.95%. The ex-dividend date of this dividend is Thursday, May 9th. Pfizer’s dividend payout ratio (DPR) is currently -2,799.53%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.